Methyl 7-methyl-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylate → 6-(Hydroxymethyl)-7-methyl-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one

HRID 639027ノート

反応式

HRID 639027 の反応式
[CH3:1][C:2]1[C:11]([C:12](OC)=[O:13])=[N:10][C:9]2[NH:8][C:7](=[O:16])[CH2:6][S:5][C:4]=2[CH:3]=1>C1COCC1>[OH:13][CH2:12][C:11]1[C:2]([CH3:1])=[CH:3][C:4]2[S:5][CH2:6][C:7](=[O:16])[NH:8][C:9]=2[N:10]=1

参加物

3

反応物 1

HCID 21873746Methyl 7-methyl-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylate

生成物 1

HCID 218736326-(Hydroxymethyl)-7-methyl-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one

試薬・触媒・溶媒 1

HCID 8028Tetrahydrofuran溶媒

反応条件

温度
-10 °C

実験手順

Methyl 7-methyl-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylate (54 mg, 0.195 mmol) was dissolved in THF (5 mL), cooled to −10° C. and treated with 1.0M LiH3BNMe2 (0.42 mL, 0.42 mmol). The reaction was maintained at −10° C. for 1 h and then quenched with 6N HCl. The reaction solution was diluted with EtOAc and water and the aqueous phase was extracted with EtOAc. The combined organic phases were dried (Na2SO4), filtered and concentrated. The crude product (30.3 mg) was used directly in the next step without further purification.

後処理

  1. additiontreated with 1.0M LiH3BNMe2 (0.42 mL, 0.42 mmol)
  2. temperatureThe reaction was maintained at −10° C. for 1 h
  3. customquenched with 6N HCl
  4. additionThe reaction solution was diluted with EtOAc and water
  5. extractionthe aqueous phase was extracted with EtOAc
  6. dry with materialThe combined organic phases were dried (Na2SO4)
  7. filtrationfiltered
  8. concentrationconcentrated
  9. customThe crude product (30.3 mg) was used directly in the next step without further purification

出典と根拠

ORDレコード
ord-44167344f08a401b8a7525f4f3482b23
出典データセット
uspto-grants-2010_04
特許番号
US07691850B2

反応ノート

読み込み中…